GLP-1
WEIGHT MANAGEMENTQuick Specifications
| Vial Size | 2MG |
|---|---|
| BAC Water | 1ML |
| Amount Per Unit | 0.02MG PER UNIT |
| Recommended Dose | TITRATE UP FROM 250MCG TO 2.5MG (12 TO 125 UNITS) |
| Frequency | 1X PER WEEK |
| Injection Type | SUBCUTANEOUS |
| Timing | Same Day Every Week / Starting Dose Is 250 MCG |
Research Overview
GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally released by the gut after eating. As a receptor agonist, it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and signals the brain's hypothalamus to reduce appetite — all through binding to GLP-1 receptors expressed in the pancreas, brain, gut, and adipose tissue. Brain-mediated appetite suppression is now considered the primary driver of its weight loss effects, with preclinical research showing that GLP-1 action restricted to the brain alone still produces significant food intake reduction. Phase 3 clinical trials with GLP-1 agonists have demonstrated mean body weight reductions of approximately 15% over 68 weeks, with approximately 50% of participants achieving 15% or more weight loss. Common research side effects include nausea, vomiting, and constipation, particularly during dose titration — which is why starting doses are low and titrated upward gradually. For research and educational purposes only. Consult a qualified healthcare professional.
How It Works
Pancreatic Beta Cell Action
GLP-1 binds receptors on pancreatic beta cells to enhance glucose-dependent insulin secretion — insulin release only occurs when blood glucose is elevated, making hypoglycemia risk lower than with traditional insulin sensitizers.
Hypothalamic Appetite Suppression
GLP-1 receptors in the brain's hypothalamus and brainstem receive signals that reduce appetite and increase satiety. Research now confirms that brain-mediated appetite suppression — not pancreatic action — is the primary driver of GLP-1's weight loss effects.
Gastric Emptying Delay
By slowing the rate at which food leaves the stomach, GLP-1 reduces the speed of glucose absorption into the bloodstream and prolongs the sensation of fullness. This mechanism also accounts for nausea experienced during early dose titration.
Commonly Studied With
These peptides are frequently researched alongside GLP-1: 2mg due to complementary mechanisms:
Research references
The following PubMed resources are provided for educational reference. External links open in a new tab.
GLP-1: 2mg information on this page is for research and educational purposes only. This content is not FDA-approved, does not constitute medical advice, and should not be used to guide personal health decisions. Consult a qualified healthcare professional before using any research compound.
Dose Calculator
Enter your target dose to calculate the volume to draw.
Recommended dose: TITRATE UP FROM 250MCG TO 2.5MG (12 TO 125 UNITS)